Sonochemical Development of Magnetic Nanoporous Therapeutic Systems as Carriers for 5-Fluorouracil
DOI:
https://doi.org/10.12974/2311-8792.2013.01.01.4Keywords:
Chemotherapeutic agents, drug nanoconfinement, controlled release, 5-fluorouracil, magnetic mesoporous silica, targeted delivery, ultrasonic irradiation.Abstract
Therapeutic nanosystems based on magnetic mesoporous silica nanoparticles are successfully obtained by a facile, reproducible and time-saving sonochemical method. Hydrophilic citrate-capped magnetite nanoparticles of about 20 nm are firstly prepared by ultrasound-assisted chemical precipitation. Secondly, freshly-dried magnetite nanoparticles are coated with mesoporous silica shell by sonochemically-modified Ströber method. The applied procedure provides easily-separable, stable core-shell nanoparticles consisting of superparamagnetic Fe3O4 cores and mesoporous silica shell. SEM micrographs showed that core-shell nanoparticles are smaller than 400 nm, a prerequisite for biomedical applications by intravenous administrations. Further, these sonochemically prepared magnetic nanoparticles are employed as biocompatible matrices to host and deliver 5-fluorouracil, a highly-toxic low-molecular antimetabolite chemotherapeutic drug. For this, drug molecules are confined into unmodified and amino-modified mesopores of the silica shell by adsorption from alcoholic solutions. A detailed study was performed using XRD, N2-sorption measurements, SEM and FTIR spectroscopy with the primary goal of investigating possible structural, textural and morphological modifications aroused after pore-functionalization and drug nanoconfinement. Magnetic behavior of prepared therapeutic nanosystems is visualized using vibrating sample magnetometry (VSM). Finally, the release profile of 5-fluorouracil from the unmodified and amino-modified nanoparticulate magnetic matrices in PBS solution (pH 7.4) is followed by means of liquid chromatographic measurements. The HPLC method used for determination of 5-fluoruracil in releasing media was fully validated in house, in terms of specificity, linearity, precision, LOD and LOQ establishment.
References
Rosenholm JM, Sahlgren C, Linden M. Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles – opportunities & challenges. Nanoscale 2010; 2: 1870-83. http://dx.doi.org/10.1039/c0nr00156b
Ranganathan R, Madanmohan S, Kesavan A, Baskar G, Krishnamoorthy YR, Santosham R, et al. Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications. Int J Nanotechn 2012; 7: 1043-60.
Pantic I. Magnetic nanoparticles in cancer diagnosis and treatment: novel approaches. Rev Adv Mater Sci 2010; 26: 67-73. http://dx.doi.org/10.2147/IJN.S25182
Varanda LC, Jafelicci Junior M, BeckJunior W. Magnetic and Multifunctional Magnetic Nanoparticles in Nanomedicine: Challenges and Trends in Synthesis and Surface Engineering for Diagnostic and Therapy Applications, in A.N. Laskovski (Ed.), Biomedical Engineering, Trends in Materials Science 2011; ISBN 978 – 953 – 307 – 513 – 6, pp. 397 – 424.
Couvreur P. Nanoparticles in drug delivery: past, present and future. Adv Drug Deliv Rev 2013; 65: 21-3. http://dx.doi.org/10.1016/j.addr.2012.04.010
Lu J, Yang S, Ming Ng K, Su C-H, Yeh C-S, Wu Y-N, et al. Solid-state synthesis of monocrystalline iron oxide nanoparticle based ferrofluid suitable for magnetic resonance imaging contrast application. Nanotechnol 2006; 17: 5812- 20. http://dx.doi.org/10.1088/0957-4484/17/23/017
Aruebo M, Fernandez-Pacheco R, Ibarra MR, Santamaria J. Magnetic nanoparticles for drug delivery. Nanotoday 2007; 2(3): 22-32. http://dx.doi.org/10.1016/S1748-0132(07)70084-1
Elias D, de Baere T, Sideris L, Ducreux M. Regional chemotherapeutic techniques for liver tumors: current knowledge and future directions. Surg Clin North Am 2004; 84: 607-25. http://dx.doi.org/10.1016/S0039-6109(03)00225-1
Jungkyun I, Goutam B, Wanil K, Kyong-Tai K, Chung S-K. A blood-brain barrier permeable derivative of 5-fluorouracil: preparation, intracellular localization, and mouse tissue distribution. Bull Korean Chem Soc 2011; 32: 873-9. http://dx.doi.org/10.5012/bkcs.2011.32.3.873
Shenoy VS, Gude RP, Ramachandra Murthy RS. In vitro anticancer evaluation of 5-fluorouracil lipid nanoparticles using B16F10 melanoma cell Lines. Int Nano Lett 2012; 2: 14-24.
Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330-8. http://dx.doi.org/10.1038/nrc1074
Noordhuis P, Holwerda U, Van der Wilt CL, Van Groeningen CJ. Smid K, Meijer S, et al. 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann Oncol 2004; 15: 1025-32. http://dx.doi.org/10.1093/annonc/mdh264
Nicolay NH, Berry DP, Sharma RA. Liver metastases from colorectal cancer: radioembolization with systemic therapy. Nat Rev Clin Oncol 2009; 6: 687-97. http://dx.doi.org/10.1038/nrclinonc.2009.165
Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier MJ, Burtin PC, et al. Relationship between 5- fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 1996; 77: 441-51. http://dx.doi.org/10.1002/(SICI)1097- 0142(19960201)77:3<441::AID-CNCR4>3.0.CO;2-N
Li S, Wang A, Jiang W, Guan Z. Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. BMC Cancer 2008; 8: 1-9. http://dx.doi.org/10.1186/1471-2407-8-103
Tomoiag???? AM, Cioroiu BI, Nica V, Vasile A. Investigations on nanoconfinement of low-molecular antineoplastic agents into biocompatible magnetic matrices for drug targeting. Coll Surf B Biointerfaces 2013; 111: 52-9. http://dx.doi.org/10.1016/j.colsurfb.2013.05.019
Larkin PJ. Infrared and Raman Spectroscopy: Principles and Spectral Interpretation. Elsevier, Amsterdam 2011.
Calvo A, Angelome PC, Sanchez VM, Scherlis DA, Williams FG. Soller – Illia GJ AA. Chem Mater 2008; 20: 4661-8. http://dx.doi.org/10.1021/cm800597k
Kim J, Seidler P, Wan LS, Fill C. Formation, structure and reactivity of amino-terminated organic films on silicon substrates. J Coll Interf Sci 2009; 329: 114-9. http://dx.doi.org/10.1016/j.jcis.2008.09.031
Dibbern HW, Müller RM, Wirbitzki E, Eds. UV and IR Spectra: Pharmaceutical Substances (UV and IR) and Pharmaceutical and Cosmetic Excipients (IR), Ed. Cantor Verlag, Aulendorf, Germany 2002.